CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) CEO Samarth Kulkarni sold 47,837 shares of the firm's stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $49.78, for a total value of $2,381,325.86. Following the transaction, the chief executive officer owned 311,899 shares in the company, valued at $15,526,332.22. This represents a 13.30% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Samarth Kulkarni also recently made the following trade(s):
- On Wednesday, October 14th, Samarth Kulkarni sold 4,098 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $49.26, for a total value of $201,867.48.
CRISPR Therapeutics Price Performance
Shares of NASDAQ CRSP opened at $49.88 on Wednesday. The company has a current ratio of 17.85, a quick ratio of 17.85 and a debt-to-equity ratio of 0.34. CRISPR Therapeutics AG has a twelve month low of $44.12 and a twelve month high of $75.06. The stock has a 50 day moving average of $54.84 and a two-hundred day moving average of $53.30. The stock has a market cap of $4.82 billion, a P/E ratio of -10.48 and a beta of 1.76.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, June 30th. The company reported ($0.94) earnings per share for the quarter. The firm had revenue of $10.18 million during the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. On average, research analysts forecast that CRISPR Therapeutics AG will post -4.48 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Swiss National Bank increased its holdings in shares of CRISPR Therapeutics by 5.1% in the first quarter. Swiss National Bank now owns 169,700 shares of the company's stock valued at $8,073,000 after purchasing an additional 8,200 shares during the period. Affinity Asset Advisors LLC purchased a new stake in shares of CRISPR Therapeutics during the first quarter worth approximately $7,136,000. Congress Asset Management Co. raised its stake in shares of CRISPR Therapeutics by 1.6% during the third quarter. Congress Asset Management Co. now owns 111,230 shares of the company's stock worth $6,153,000 after purchasing an additional 1,777 shares during the last quarter. KBC Group NV lifted its holdings in shares of CRISPR Therapeutics by 3,999.9% during the first quarter. KBC Group NV now owns 116,847 shares of the company's stock worth $5,558,000 after purchasing an additional 113,997 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in shares of CRISPR Therapeutics by 29.6% during the first quarter. California State Teachers Retirement System now owns 101,232 shares of the company's stock worth $4,816,000 after purchasing an additional 23,109 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. UBS Group started coverage on shares of CRISPR Therapeutics in a research note on Thursday, October 15th. They issued a "neutral" rating and a $52.00 price objective on the stock. HC Wainwright restated a "buy" rating on shares of CRISPR Therapeutics in a research note on Friday, October 9th. Needham & Company LLC reaffirmed a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Monday, August 31st. Finally, William Blair upgraded shares of CRISPR Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $65.75.
Read Our Latest Stock Analysis on CRISPR Therapeutics
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company's research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.
Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
